{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:57:01Z","timestamp":1788177421233,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11586-y","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T13:50:35Z","timestamp":1759153835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intermittent loss of anti-HBc antibodies in people with multiple sclerosis undergoing disease-modifying therapies"],"prefix":"10.1186","volume":"25","author":[{"given":"Patrizia","family":"Pasculli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann Collins Fosso","family":"Ngangue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonella","family":"Zingaropoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Dominelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ciccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Antonacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Ferrazzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Campagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Turriziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio Maria","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosa","family":"Ciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"11586_CR1","unstructured":"Barkhane Z, Elmadi J, Satish Kumar L, Pugalenthi LS, Ahmad M, Reddy S. Multiple sclerosis and autoimmunity: A veiled relationship. Cureus 14:e24294."},{"key":"11586_CR2","doi-asserted-by":"publisher","first-page":"824926","DOI":"10.3389\/fneur.2022.824926","volume":"13","author":"JH Yang","year":"2022","unstructured":"Yang JH, Rempe T, Whitmire N, Dunn-Pirio A, Graves JS. Therapeutic advances in multiple sclerosis. Front Neurol. 2022;13:824926.","journal-title":"Front Neurol"},{"key":"11586_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41582-018-0082-z","volume":"15","author":"M Tintore","year":"2019","unstructured":"Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis - success from bench to bedside. Nat Rev Neurol. 2019;15:53\u20138.","journal-title":"Nat Rev Neurol"},{"key":"11586_CR4","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41573-022-00477-5","volume":"21","author":"L Bierhansl","year":"2022","unstructured":"Bierhansl L, Hartung H-P, Aktas O, Ruck T, Roden M, Meuth SG. Thinking outside the box: non-canonical targets in multiple sclerosis. Nat Rev Drug Discov. 2022;21:578\u2013600.","journal-title":"Nat Rev Drug Discov"},{"key":"11586_CR5","first-page":"1315","volume":"70","author":"W Br\u00fcck","year":"2013","unstructured":"Br\u00fcck W, Gold R, Lund BT, Oreja-Guevara C, Prat A, Spencer CM, et al. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol. 2013;70:1315\u201324.","journal-title":"JAMA Neurol"},{"key":"11586_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/1352458520952311","volume":"27","author":"L Moiola","year":"2021","unstructured":"Moiola L, Barcella V, Benatti S, Capobianco M, Capra R, Cinque P, et al. The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. Mult Scler. 2021;27:331\u201346.","journal-title":"Mult Scler"},{"key":"11586_CR7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/14740338.2019.1612872","volume":"18","author":"F Cantini","year":"2019","unstructured":"Cantini F, Niccoli L, Capone A, Petrone L, Goletti D. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf. 2019;18:415\u201325.","journal-title":"Expert Opin Drug Saf"},{"key":"11586_CR8","first-page":"205521732110657","volume":"8","author":"MA Zingaropoli","year":"2022","unstructured":"Zingaropoli MA, Pasculli P, Iannetta M, Perri V, Tartaglia M, Crisafulli SG, et al. Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study. Mult Scler J Exp Transl Clin. 2022;8:20552173211065731.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"11586_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12974-019-1517-1","volume":"16","author":"BM Arneth","year":"2019","unstructured":"Arneth BM. Impact of B cells to the pathophysiology of multiple sclerosis. J Neuroinflammation. 2019;16:128.","journal-title":"J Neuroinflammation"},{"key":"11586_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, et al. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221\u201334.","journal-title":"N Engl J Med"},{"key":"11586_CR11","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Belachew S, Wolinsky JS. Ocrelizumab in primary progressive and relapsing multiple sclerosis. N Engl J Med. 2017;376:1694.","journal-title":"N Engl J Med"},{"key":"11586_CR12","doi-asserted-by":"publisher","first-page":"ofz445","DOI":"10.1093\/ofid\/ofz445","volume":"6","author":"E Zappulo","year":"2019","unstructured":"Zappulo E, Buonomo AR, Sacc\u00e0 F, Russo CV, Scotto R, Scalia G, et al. Incidence and predictive risk factors of infective events in patients with multiple sclerosis treated with agents targeting CD20 and CD52 surface antigens. Open Forum Infect Dis. 2019;6:ofz445.","journal-title":"Open Forum Infect Dis"},{"key":"11586_CR13","first-page":"587","volume":"12","author":"MA Zingaropoli","year":"2023","unstructured":"Zingaropoli MA, Pasculli P, Tartaglia M, Dominelli F, Ciccone F, Taglietti A, et al. Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated PwMS and infectious risk. Biology (Basel). 2023;12:587.","journal-title":"Biology (Basel)"},{"key":"11586_CR14","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1007\/s00415-022-11009-x","volume":"269","author":"AR Buonomo","year":"2022","unstructured":"Buonomo AR, Viceconte G, Calabrese M, De Luca G, Tomassini V, Cavalla P, et al. Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. J Neurol. 2022;269:3301\u20137.","journal-title":"J Neurol"},{"key":"11586_CR15","doi-asserted-by":"publisher","first-page":"ofy356","DOI":"10.1093\/ofid\/ofy356","volume":"6","author":"MR Ciardi","year":"2018","unstructured":"Ciardi MR, Iannetta M, Zingaropoli MA, Salpini R, Aragri M, Annecca R, et al. Reactivation of hepatitis B virus with Immune-Escape mutations after Ocrelizumab treatment for multiple sclerosis. Open Forum Infect Dis. 2018;6:ofy356.","journal-title":"Open Forum Infect Dis"},{"key":"11586_CR16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1473-3099(02)00315-8","volume":"2","author":"J-H Kao","year":"2002","unstructured":"Kao J-H, Chen D-S. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2:395\u2013403.","journal-title":"Lancet Infect Dis"},{"key":"11586_CR17","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","volume":"388","author":"JD Stanaway","year":"2016","unstructured":"Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet. 2016;388:1081\u20138.","journal-title":"Lancet"},{"key":"11586_CR18","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.3390\/diagnostics11122185","volume":"11","author":"GP Caviglia","year":"2021","unstructured":"Caviglia GP, Zorzi A, Rizzetto M, Mirandola M, Olivero A, Carolo G. Hepatitis B virus reactivation upon immunosuppression: is there a role for hepatitis B Core-Related antigen in patients with Immune-Escape mutants?? A case report. Diagnostics (Basel). 2021;11:2185.","journal-title":"Diagnostics (Basel)"},{"key":"11586_CR19","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European association for the study of the liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u201398.","journal-title":"J Hepatol"},{"key":"11586_CR20","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jhep.2008.07.014","volume":"49","author":"G Raimondo","year":"2008","unstructured":"Raimondo G, Allain J-P, Brunetto MR, Buendia M-A, Chen D-S, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49:652\u20137.","journal-title":"J Hepatol"},{"key":"11586_CR21","doi-asserted-by":"publisher","first-page":"e487","DOI":"10.1200\/JOP.2015.004846","volume":"11","author":"JP Hwang","year":"2015","unstructured":"Hwang JP, Artz AS, Somerfield MR. Hepatitis B virus screening for patients with cancer before therapy: American society of clinical oncology provisional clinical opinion update. J Oncol Pract. 2015;11:e487\u2013489.","journal-title":"J Oncol Pract"},{"key":"11586_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","volume":"148","author":"RP Perrillo","year":"2015","unstructured":"Perrillo RP, Gish R, Falck-Ytter YT. American gastroenterological association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:221\u2013e2443.","journal-title":"Gastroenterology"},{"key":"11586_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00415-023-11973-y","volume":"271","author":"B Marzo","year":"2024","unstructured":"Marzo B, Vidal-Jordana A, Castill\u00f3 J, Robles-Sanchez M-A, Otero-Romero S, Tintore M, et al. Hepatitis B reactivation is a rare event among patients with resolved infection undergoing anti-CD20 antibodies in monotherapy without antiviral prophylaxis: results from the HEBEM study. J Neurol. 2024;271:134\u201340.","journal-title":"J Neurol"},{"key":"11586_CR24","doi-asserted-by":"publisher","first-page":"104490","DOI":"10.1016\/j.msard.2022.104490","volume":"70","author":"F Ladeira","year":"2023","unstructured":"Ladeira F, Oliveira T, Soares M, Araujo C, Sousa A, Brum M, et al. HBV and VZV seroprotection loss in MS patients under DMT. Mult Scler Relat Disord. 2023;70:104490.","journal-title":"Mult Scler Relat Disord"},{"key":"11586_CR25","doi-asserted-by":"publisher","first-page":"175628641983657","DOI":"10.1177\/1756286419836571","volume":"12","author":"L Klotz","year":"2019","unstructured":"Klotz L, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S, et al. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord. 2019;12:1756286419836571.","journal-title":"Ther Adv Neurol Disord"},{"key":"11586_CR26","unstructured":"CDC. Clinical Testing and Diagnosis for Hepatitis, Hepatitis B. B. 2024. https:\/\/www.cdc.gov\/hepatitis-b\/hcp\/diagnosis-testing\/index.html. Accessed 29 Jul 2024."},{"issue":"12 Suppl 2","key":"11586_CR27","doi-asserted-by":"publisher","first-page":"S343","DOI":"10.1093\/infdis\/jiaa668","volume":"224","author":"J Pattyn","year":"2021","unstructured":"Pattyn J, Hendrickx G, Vorsters A, Van Damme P, Hepatitis B, Vaccines. J Infect Dis. 2021;224(12 Suppl 2):S343\u201351.","journal-title":"J Infect Dis"},{"key":"11586_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jcv.2017.06.001","volume":"93","author":"OE Anastasiou","year":"2017","unstructured":"Anastasiou OE, Widera M, Verheyen J, Korth J, Gerken G, Helfritz FA, et al. Clinical course and core variability in HBV infected patients without detectable anti-HBc antibodies. J Clin Virol. 2017;93:46\u201352.","journal-title":"J Clin Virol"},{"key":"11586_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jcv.2006.03.014","volume":"38","author":"BC G\u00e4rtner","year":"2007","unstructured":"G\u00e4rtner BC, Jung W, Welsch C, Fischinger J, Schubert J, Zeuzem S, et al. Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantation. J Clin Virol. 2007;38:146\u20138.","journal-title":"J Clin Virol"},{"key":"11586_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3390\/vaccines10020137","volume":"10","author":"C Holtkamp","year":"2022","unstructured":"Holtkamp C, Fiedler M, Dittmer U, Anastasiou OE. The course of Anti-HBc antibodies over time in immunocompromised hosts. Vaccines (Basel). 2022;10:137.","journal-title":"Vaccines (Basel)"},{"issue":"Supplement 1","key":"11586_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2020-142393","volume":"136","author":"J Ren","year":"2020","unstructured":"Ren J, Chen D, Zheng R, Zhang Y, Xu J, Luo X, et al. Changes of hepatitis B immune status after allogeneic hematopoietic stem cell transplantation in HBsAg Negative\/Anti-Hbc positive patients: A single center observational study. Blood. 2020;136(Supplement 1):28.","journal-title":"Blood"},{"key":"11586_CR32","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3390\/jcm9010202","volume":"9","author":"F Moretto","year":"2020","unstructured":"Moretto F, Catherine F-X, Esteve C, Blot M, Piroth L. Isolated Anti-HBc: significance and management. J Clin Med. 2020;9:202.","journal-title":"J Clin Med"},{"key":"11586_CR33","first-page":"31","volume":"2","author":"K Loh","year":"2007","unstructured":"Loh K, Kew S. Interpreting hepatitis B serology. Malays Fam Physician. 2007;2:31\u20132.","journal-title":"Malays Fam Physician"},{"key":"11586_CR34","doi-asserted-by":"publisher","first-page":"1050183","DOI":"10.3389\/fimmu.2022.1050183","volume":"13","author":"F Dominelli","year":"2022","unstructured":"Dominelli F, Zingaropoli MA, Tartaglia M, Tortellini E, Guardiani M, Perri V, et al. Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine. Front Immunol. 2022;13:1050183.","journal-title":"Front Immunol"},{"key":"11586_CR35","doi-asserted-by":"publisher","first-page":"796482","DOI":"10.3389\/fimmu.2021.796482","volume":"12","author":"M Iannetta","year":"2021","unstructured":"Iannetta M, Landi D, Cola G, Campogiani L, Malagnino V, Teti E, et al. B- and T-Cell responses after SARS-CoV-2 vaccination in patients with multiple sclerosis receiving disease modifying therapies: immunological patterns and clinical implications. Front Immunol. 2021;12:796482.","journal-title":"Front Immunol"},{"key":"11586_CR36","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1177\/13524585251318513","volume":"31","author":"R Carvajal","year":"2025","unstructured":"Carvajal R, Tur C, Borras-Bermejo B, Saylor D, Montalban X, Tintor\u00e9 M, et al. Vaccination in multiple sclerosis: tackling challenges and paving the way for effective immunization. Mult Scler. 2025;31:754\u201363.","journal-title":"Mult Scler"},{"key":"11586_CR37","doi-asserted-by":"crossref","unstructured":"Gabeli\u0107 T, Barun B, Adamec I, Krbot Skori\u0107 M, Habek M. Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis. Hum Vaccin Immunother 17:4345\u201362.","DOI":"10.1080\/21645515.2021.1969850"},{"key":"11586_CR38","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1001\/jama.2013.281115","volume":"310","author":"M Mitka","year":"2013","unstructured":"Mitka M. FDA: increased HBV reactivation risk with ofatumumab or rituximab. JAMA. 2013;310:1664.","journal-title":"JAMA"},{"key":"11586_CR39","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.neurol.2019.08.012","volume":"176","author":"V Pourcher","year":"2020","unstructured":"Pourcher V. What are the infectious risks with disease-modifying drugs for multiple sclerosis and how to reduce them? A review of literature. Rev Neurol (Paris). 2020;176:235\u201343.","journal-title":"Rev Neurol (Paris)"},{"key":"11586_CR40","doi-asserted-by":"publisher","first-page":"189","DOI":"10.36740\/Merkur202303101","volume":"51","author":"N Niedziela","year":"2023","unstructured":"Niedziela N, Zimnol A, Lubczy\u0144ski M, Szymbara P, Kubicka-B\u0105czyk K, Jaroszewicz J, et al. OCRELIZUMAB THERAPY IN PATIENTS WITH ANTI-HBC ANTIBODIES - A PRELIMINARY STUDY. Pol Merkur Lekarski. 2023;51:189\u201393.","journal-title":"Pol Merkur Lekarski"},{"key":"11586_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrneurol.2012.8","volume":"8","author":"M Loebermann","year":"2012","unstructured":"Loebermann M, Winkelmann A, Hartung H-P, Hengel H, Reisinger EC, Zettl UK. Vaccination against infection in patients with multiple sclerosis. Nat Rev Neurol. 2012;8:143\u201351.","journal-title":"Nat Rev Neurol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11586-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11586-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11586-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:02:26Z","timestamp":1759190546000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11586-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11586"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11586-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Policlinico Umberto I, Sapienza University of Rome (protocol number 130\/13 and 353\/20). All pwMS gave written informed consent for participation in the study. The study was conducted in accordance with the principles outlined in the Declaration of Helsinki and adhered to applicable national guidelines for biomedical research involving human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1179"}}